国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (6): 476-479.doi: 10.3760/cma.j.issn.1673422X.2014.06.022

• 论著 • 上一篇    下一篇

奈达铂同期放化疗治疗中晚期宫颈癌前瞻性临床研究

叶伟军,徐敏,曹新平,金华,刘红英   

  1. 510060 广州，华南肿瘤学国家重点实验室 中山大学肿瘤防治中心放射治疗科（叶伟军、曹新平、刘红英）；新疆医科大学附属肿瘤医院妇瘤放疗科(徐敏、金华)
  • 出版日期:2014-06-08 发布日期:2014-05-08
  • 通讯作者: 叶伟军，Email：yewj@sysucc.org.cn E-mail:yewj@sysucc.org.cn
  • 基金资助:

    广东省科技计划项目（2009B080701011）

A prospective clinical study of concurrent chemoradiotherapy with nedaplatin for patients with middleadvanced stage uterine cervical carcinoma

 YE  Wei-Jun, XU  Min, CAO  Xin-Ping, JIN  Hua, LIU  Hong-Ying   

  1. *Department of Radiotherapy, State Key Laboratory of Oncology in South China, Cancer Center, Sun YatSen University, Guangzhou 510060, China
  • Online:2014-06-08 Published:2014-05-08
  • Contact: Ye Weijun E-mail:yewj@sysucc.org.cn

PDF

1417

被引次数

7

摘要： 目的探讨顺铂同期放化疗与奈达铂同期放化疗治疗中晚期宫颈癌的疗效和不良反应。方法180例中晚期宫颈癌患者随机分为奈达铂同期放化疗组（奈达铂组90例）和顺铂同期放化疗组（顺铂组90例），观察并比较2组的近期疗效及不良反应。结果奈达铂组近期有效率、1年无复发生存率、1年无转移生存率、2年无复发生存率、2年无转移生存率分别为98.85%、89.66、86.21%、85.06%和80.46%，顺铂组近期有效率、1年无复发生存率、1年无转移生存率、2年无复发生存率、2年无转移生存率分别分别为97.60%（χ2=3.07，P＞0.05）、81.93%（χ2=3.07，P＞0.05）、83.13%（χ2=0.31，P＞0.05）、78.31%（χ2=1.30，P＞0.05）和80.72%（χ2=0.00，P＞0.05），两组间差异无统计学意义。顺铂组恶心呕吐总发生率及Ⅲ～Ⅳ级发生率分别为52.27%、12.50%，明显高于奈达铂组的27.27%、6.82%（χ2=12.18,P=0.01），而贫血、白细胞减少、血小板减少、腹泻等不良反应两组间无明显差异。结论奈达铂同期放化疗疗效与顺铂同期放化疗相同，不良反应可以耐受。

关键词: 宫颈肿瘤, 放射疗法, 药物疗法

Abstract: ObjectiveTo investigate the efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin versus cisplatin for patients with middleadvanced stage uterine cervical carcinoma.Methods180 patients with middleadvanced stage uterine cervical carcinoma were randomized into concurrent chemoradiotherapy with nedaplatin group (nedaplatin group) and concurrent chemoradiotherapy with cisplatin group (cisplatin group). The shortterm efficacy and the toxicity were observed.ResultsIn  the nedaplatin group , the shortterm response rate、the oneyear relapsefree surviva l、oneyea metastasisfree survival、the twoyear relapsefree survival、the twoyear metastasisfree survival  were 98.85%、 89.66、86.21%、85.06%和80.46% , But in the cisplatin group, the shortterm response rate、the oneyear relapsefree surviva l、oneyea metastasisfree survival、the twoyear relapsefree survival、the twoyear metastasisfree survival  were 97.60%（χ2=3.07，P＞0.05）、81.93%（χ2=3.07，P＞0.05）、83.13%（χ2=0.31，P＞0.05）、78.31%（χ2=1.30，P＞0.05）和80.72%（χ2=0.00，P＞0.05）, so there was no significant difference. The incidences of nausea and vomiting in the cisplatin group were 52.27% (grade Ⅰ～Ⅳ toxicities)，12.50% (grade Ⅲ～Ⅳ toxicities), which were higher than those in the nedaplatin group 27.27% (grade Ⅰ～Ⅳ toxicities)，6.82% (grade Ⅲ～Ⅳ toxicities)(P＜0.05), while there were no significant difference in the other toxicities such as anemia，granulocytopenia，thrombocytopenia，diarrhoea between the two groups (χ2=12.18,P＞0.05).ConclusionThe efficacy of concurrent chemoradiotherapy with  nedaplatin is the same as that of  concurrent chemoradiotherapy with cisplatin, and its toxicity is welltolerated.

Key words: Uterine cervical neoplasms, Radiotherapy, Drug therapy